Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use; D002460:Cell Line; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000601:surgery* / Q000628:therapy*; D008937:Mitomycins / Q000494:pharmacology; D009364:Neoplasm Recurrence, Local; D009439:Neuraminidase / Q000494:pharmacology; D011897:Random Allocation; D012673:Semustine / Q000009:adverse effects / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000601:surgery / Q000628:therapy*; D013997:Time Factors
D001500:BCG Vaccine; D008937:Mitomycins; D012673:Semustine; D009439:Neuraminidase